Adicet Bio, Inc. (ACET) Current Ratio
- Current ratio · latest quarter: Value 6.71×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.71× | Current assets / current liabilities. $120.76M ÷ $18.00M ≈ 6.71× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 120.76M USD | Assets, Current |
| Current obligations | 18.00M USD | Liabilities, Current |
| Cash and equivalents | 33.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.59M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.76M | $18.00M | $33.13M | (m) | (m) | (m) | $3.59M | (m) | 6.71× |
| 2026-03-31 | $140.07M | $18.30M | $36.24M | (m) | (m) | (m) | $2.93M | (m) | 7.65× |
| 2025-12-31 | $160.93M | $21.53M | $38.92M | (m) | (m) | (m) | $4.74M | (m) | 7.47× |
| 2025-09-30 | $106.49M | $18.94M | $29.10M | (m) | (m) | (m) | $4.29M | (m) | 5.62× |
| 2025-06-30 | $127.74M | $17.08M | $34.72M | (m) | (m) | (m) | $3.29M | (m) | 7.48× |
| 2025-03-31 | $153.56M | $16.45M | $28.13M | (m) | (m) | (m) | $4.40M | (m) | 9.34× |
| 2024-12-31 | $180.14M | $19.39M | $56.49M | (m) | (m) | (m) | $4.83M | (m) | 9.29× |
| 2024-09-30 | $206.32M | $19.39M | $105.48M | (m) | (m) | (m) | $2.50M | (m) | 10.64× |
| 2024-06-30 | $228.35M | $17.90M | $224.07M | (m) | (m) | (m) | $1.90M | (m) | 12.75× |
| 2024-03-31 | $250.35M | $17.46M | $247.59M | (m) | (m) | (m) | $2.54M | (m) | 14.34× |
| 2023-12-31 | $162.27M | $19.29M | $159.71M | (m) | (m) | (m) | $2.63M | (m) | 8.41× |
| 2023-09-30 | $185.88M | $19.77M | $183.26M | (m) | (m) | (m) | $4.07M | (m) | 9.40× |
| 2023-06-30 | $208.66M | $18.84M | $205.46M | (m) | (m) | (m) | $3.12M | (m) | 11.08× |
| 2023-03-31 | $234.81M | $18.09M | $231.64M | (m) | (m) | (m) | $2.75M | (m) | 12.98× |
| 2022-12-31 | $261.04M | $19.71M | $257.66M | (m) | (m) | (m) | $4.40M | (m) | 13.25× |
| 2022-09-30 | $285.74M | $17.22M | $282.68M | (m) | (m) | (m) | $4.57M | (m) | 16.59× |
| 2022-06-30 | $264.09M | $16.40M | $260.64M | (m) | (m) | (m) | $4.15M | (m) | 16.10× |
| 2022-03-31 | $281.53M | $10.40M | $277.88M | (m) | (m) | (m) | $3.46M | (m) | 27.07× |
| 2021-12-31 | $282.44M | $16.32M | $277.54M | (m) | (m) | (m) | $3.26M | (m) | 17.31× |
| 2021-09-30 | $199.03M | $20.03M | $192.23M | $0.00 | (m) | (m) | $4.63M | (m) | 9.94× |
| 2021-06-30 | $216.30M | $20.95M | $208.73M | $0.00 | (m) | (m) | $2.32M | (m) | 10.33× |
| 2021-03-31 | $229.11M | $25.18M | $221.67M | $1.75M | (m) | (m) | $1.75M | (m) | 9.10× |
| 2020-12-31 | $100.34M | $22.48M | $84.33M | $10.28M | (m) | (m) | $1.55M | (m) | 4.46× |
| 2020-09-30 | $117.41M | $30.08M | $84.96M | $23.16M | (m) | (m) | $3.84M | (m) | 3.90× |
| 2020-06-30 | $73.75M | $3.56M | $70.89M | $0.00 | (m) | (m) | $2.47M | (m) | 20.69× |
| 2020-03-31 | $77.58M | $2.56M | $61.23M | (m) | (m) | (m) | $1.21M | (m) | 30.25× |
| 2019-12-31 | $64.19M | $14.87M | $10.61M | $51.79M | (m) | (m) | $1.05M | (m) | 4.32× |
| 2019-09-30 | $121.28M | $12.19M | $23.62M | (m) | (m) | (m) | $9.97M | (m) | 9.95× |
| 2019-06-30 | $136.09M | $9.71M | $21.37M | (m) | (m) | (m) | $8.24M | (m) | 14.02× |
| 2019-03-31 | $144.68M | $4.61M | $7.18M | (m) | (m) | (m) | $3.36M | (m) | 31.39× |
| 2018-12-31 | $109.53M | $5.72M | $7.04M | (m) | (m) | (m) | $2.99M | (m) | 19.16× |
| 2018-09-30 | $117.02M | $8.06M | $22.86M | $92.52M | (m) | (m) | $4.20M | (m) | 14.51× |
| 2018-06-30 | $128.37M | $11.59M | $51.35M | $74.57M | (m) | (m) | $4.52M | (m) | 11.08× |
| 2018-03-31 | $136.84M | $6.83M | $135.71M | (m) | (m) | (m) | $1.48M | (m) | 20.02× |
| 2017-12-31 | $55.15M | $5.50M | $53.35M | $0.00 | (m) | (m) | $1.51M | (m) | 10.02× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |